Big biotech Amgen (AMGN) was trading up Friday after it announced a cancer collaboration with Merck (MRK) and filed for its first biosimilar approval, despite a tepid initiation report from Wells Fargo. Amgen and Merck said that they are launching a study combining Merck’s Keytruda, which is currently used to treat melanoma and non-small-cell lung cancer, with Amgen’s leukemia drug Blincyto, in a study of patients with diffuse large B-cell
Big biotech Amgen beat Wall Street’s Q3 estimates and offered mixed guidance late Wednesday, sending the stock up modestly in after-hours trading. Amgen (AMGN) reported adjusted earnings of $2.72 a share, up 18% from a year earlier and beating analysts’ consensus by 34 cents, according to Thomson Reuters. Revenue climbed 14% to $5.72 billion, about $400 million above consensus and the best gain in several years. Amgen lifted its
More earnings reports flooded in late Wednesday, with Amgen (AMGN), PayPal (PYPL), Buffalo Wild Wings (BWLD) and GoPro (GPRO) leading the after-hours action: Amgen’s Q3 EPS rose 18% to $2.72, crushing views by 34 cents. Revenue grew 14% to $5.72 billion, Amgen’s best sales gain in several years. The biotech raised its full-year guidance, but the implied Q4 target may be light. Amgen’s 2016 guidance was mixed. Shares rose 1% late. PayPal’s